Despite their significant role in the early stages of tumour development, the prognostic value of the IDH mutation in chondrosarcoma seems controversial and (pre)clinical studies that have focused on the direct and indirect targeting of the IDH mutation have not yielded novel treatment strategies. Here, IDH2 is linked to chondrosarcoma.